Payment overview · 2025
General Payments
$61.28
3 reported records · 3 companies
Healthcare provider profile · identity verified
Matthew J Comeau, DO, PHD
Allopathic & Osteopathic Physicians|Internal Medicine · PLAINVILLE, KS · NPI 1154345478
Verified facts
What the public records show
CMS Open Payments records show Matthew J Comeau, DO, PHD received $61.28 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 48.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.51 | 48.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.79 | 29.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.98 | 22.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.28 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 456 | 115 |
| Gabapentin | Gabapentin | 384 | 58 |
| Prednisone | Prednisone | 374 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 68 |
| Lisinopril | Lisinopril | 317 | 87 |
| Omeprazole | Omeprazole | 307 | 70 |
| Losartan Potassium | Losartan Potassium | 281 | 66 |
| Oxycodone Hcl | Oxycodone Hcl | 277 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 245 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 243 | 71 |
| Pregabalin | Pregabalin | 225 | 32 |
| Montelukast Sodium | Montelukast Sodium | 221 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 54 |
| Furosemide | Furosemide | 215 | 52 |
| Glipizide Er | Glipizide | 200 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 196 | 51 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 180 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 176 | 27 |
| Celecoxib | Celecoxib | 163 | 30 |
| Metformin Hcl | Metformin Hcl | 161 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 41 |
| Alprazolam | Alprazolam | 150 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 35 |
| Tramadol Hcl | Tramadol Hcl | 134 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 28 |
| Propranolol Hcl | Propranolol Hcl | 120 | 25 |
| Trazodone Hcl | Trazodone Hcl | 118 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 30 |
| Alendronate Sodium | Alendronate Sodium | 113 | 24 |
| Simvastatin | Simvastatin | 111 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 24 |
| Famotidine | Famotidine | 106 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 18 |
| Sertraline Hcl | Sertraline Hcl | 98 | 24 |
| Diazepam | Diazepam | 94 | 14 |
| Spironolactone | Spironolactone | 90 | 21 |
| Ezetimibe | Ezetimibe | 85 | 26 |
| Ibuprofen | Ibuprofen | 85 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 19 |
| Clonazepam | Clonazepam | 75 | 12 |
| Lorazepam | Lorazepam | 74 | suppressed |
| Ondansetron Odt | Ondansetron | 70 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 16 |
| Eliquis | Apixaban | 67 | 18 |
| Finasteride | Finasteride | 66 | 15 |
| Metformin Hcl Er | Metformin Hcl | 66 | 12 |
| Allopurinol | Allopurinol | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 15 |
| Potassium Chloride | Potassium Chloride | 61 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 15 |
| Bupropion Xl | Bupropion Hcl | 60 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 13 |
| Bumetanide | Bumetanide | 57 | 11 |
| Meloxicam | Meloxicam | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Carvedilol | Carvedilol | 51 | 11 |
| Ozempic | Semaglutide | 51 | 11 |
| Atenolol | Atenolol | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Topiramate | Topiramate | 46 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 16 |
| Buspirone Hcl | Buspirone Hcl | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 16 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 17 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 24 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Nystatin | Nystatin | 29 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.28 · 3 records | ABBVIE INC. | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, EVENITY, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error